These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36485092)

  • 21. [Acute leukemia in adults].
    Eigendorff E; Hochhaus A
    Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?
    Boissel N; Baruchel A
    Blood; 2018 Jul; 132(4):351-361. PubMed ID: 29895662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute lymphoblastic leukemia in adolescents and young adults.
    Rytting ME; Jabbour EJ; O'Brien SM; Kantarjian HM
    Cancer; 2017 Jul; 123(13):2398-2403. PubMed ID: 28328172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of adult acute lymphoblastic leukemia.
    Gökbuget N; Hoelzer D
    Semin Hematol; 2009 Jan; 46(1):64-75. PubMed ID: 19100369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
    Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
    Yurkiewicz I; Craig J; Muffly L
    Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.
    Ribera JM; Morgades M; Montesinos P; Tormo M; Martínez-Carballeira D; González-Campos J; Gil C; Barba P; García-Boyero R; Coll R; Pedreño M; Ribera J; Mercadal S; Vives S; Novo A; Genescà E; Hernández-Rivas JM; Bergua J; Amigo ML; Vall-Llovera F; Martínez-Sánchez P; Calbacho M; García-Cadenas I; Garcia-Guiñon A; Sánchez-Sánchez MJ; Cervera M; Feliu E; Orfao A;
    Cancer Med; 2020 Apr; 9(7):2317-2329. PubMed ID: 32022463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations.
    Jain H; Rajendra A; Sengar M; Goli VB; Thorat J; Muthuluri H; Tongaonkar AH; Kota KK; Gupta H; Sharma N; Eipe T; Mehta H
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):845-860. PubMed ID: 35734814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.
    Wolach O; Amitai I; DeAngelo DJ
    Br J Haematol; 2017 Dec; 179(5):705-723. PubMed ID: 29076138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
    PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X
    Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study.
    Gidman W; Shah S; Zhang L; McKendrick J; Cong Z; Cohan D; Ottmann O
    Adv Ther; 2019 Nov; 36(11):3017-3029. PubMed ID: 31586302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state.
    Saadeh SS; Litzow MR
    Expert Rev Hematol; 2018 Mar; 11(3):195-207. PubMed ID: 29376437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
    Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-transplant achievement of negativity in minimal residual disease and French-American-British L1 morphology predict superior outcome after allogeneic transplant for Philadelphia chromosome positive acute lymphoblastic leukemia: an analysis of Southeast Asian patients.
    Ma L; Hao S; Diong C; Goh YT; Gopalakrishnan S; Ho A; Hwang W; Koh LP; Koh M; Lim ZY; Loh Y; Poon M; Tan LK; Tan P; Linn YC
    Leuk Lymphoma; 2015 May; 56(5):1362-9. PubMed ID: 25139689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
    Yoon JH; Min GJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
    Cancer; 2019 Mar; 125(6):873-883. PubMed ID: 30521062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Acute lymphoblastic leukemia in adolescents and young adults: from the viewpoint of pediatricians].
    Koh K
    Rinsho Ketsueki; 2017; 58(8):1024-1030. PubMed ID: 28883265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
    Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Hara R; Onizuka M; Kikkawa E; Shiraiwa S; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Ogawa Y; Kawada H; Matsushita H; Ando K
    Ann Hematol; 2021 Oct; 100(10):2479-2486. PubMed ID: 34247299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.